Prevalence of Carbapenem-resistance and Molecular Detection of Carbapenemase Genes of blaIMP-1 and blaVIM-2 in Pseudomonas aeruginosa isolated from Ventilated Intensive Care Unit Patients

Renas Othman  Mohammed; Karzan Sidiq

doi:10.24017/science.2026.1.16

Authors

Renas Othman Mohammed Medical Laboratory Science Department, College of Science, Charmo University, Sulaymaniyah, Iraq. https://orcid.org/0009-0008-7766-8945
Karzan R. Sidiq Medical Laboratory Science Department, College of Science, Charmo University, Sulaymaniyah, Iraq. https://orcid.org/0000-0002-6992-1954

Abstract

Pseudomonas aeruginosa (P. aeruginosa) is a life-threatening pathogen in intensive care unit (ICU). The rise of bacterial resistance to carbapenem is a major global health concern due to dwindling treatment options. This study investigated the prevalence of carbapenem-resistant P. aeruginosa (CRPA) and its imipenemase-1 metallo-β-lactamase (bla_IMP-1) and verona-integron encoded metallo-beta-lactamase 2 (bla_VIM-2) genes in ventilated ICU patients. From November 2024 to March 2025, 150 respiratory samples (sputum and bronchial wash) were collected from ICU patients in Sulaymaniyah, Iraq. The isolates were identified using standard microbiological examinations, the BD Phoenix™ M50 system and 16S rRNA sequencing for CRPA isolates only. Carbapenemase activity was phenotypically assessed via the modified carbapenem inactivation method (mCIM), while polymerase chain reaction was used to target the carbapenemase-encoding genes. The prevalence rate of P. aeruginosa was 33.3% (50/150), including 6.6% (10/150) CRPA among all patients and 20% (10/50) CRPA in P. aeruginosa positive cases. Clinically significant antimicrobial resistance patterns of 5 (10%) MDR and 8 (16%) XDR were observed in P. aeruginosa, predominately including CRPA in both categories. Genotypic analysis revealed that none of the CRPA isolates carried the bla_VIM-2 gene, whereas 20% (2/10) isolates harbored the bla_IMP-1 gene in chromosomal DNA and plasmid-enriched DNA, suggesting potential plasmid association and horizontal gene transfer risk. The mCIM assay also confirmed carbapenemase activity only in bla_IMP-1 gene positive isolates, suggesting that other resistance mechanisms may play a role in evading carbapenems. This study underscores an urgent need for intensive molecular surveillance in ICU, as the plasmid-mediated bla_IMP-1 gene could lead to hardly controllable nosocomial infections.

Keywords:

Pseudomonas aeruginosa, Carbapenem-resistance, blaIMP-1 gene, blaVIM-2 gene, Ventilated patients, Intensive care unit

References

Z. Pang, R. Raudonis, B. R. Glick, T. -J. Lin, and Z. Cheng, “Antibiotic resistance in Pseudomonas aeruginosa: mech-anisms and alternative therapeutic strategies,” Biotechnology advances, vol. 37, no. 1, pp. 177–192, Jan. 2019, doi: 10.1016/j.biotechadv.2018.11.013. DOI: https://doi.org/10.1016/j.biotechadv.2018.11.013

D. H. Halat and C. A. Moubareck, “The Intriguing Carbapenemases of Pseudomonas aeruginosa: Current Status, Genetic Profile, and Global Epidemiology,” Yale Journal of Biology and Medicine, vol. 95, no. 4, pp. 507–515, Dec. 2022.

D. M. Livermore, “Multiple Mechanisms of Antimicrobial Resistance in Pseudomonas aeruginosa: Our Worst Nightmare?,” Clinical Infectious Diseases, vol. 34, no. 5, pp. 634–640, Mar. 2002, doi: 10.1086/338782. DOI: https://doi.org/10.1086/338782

E.-J. Yoon and S. H. Jeong, “Mobile Carbapenemase Genes in Pseudomonas aeruginosa,” Frontiers in Microbiology, vol. 12, Feb. 2021, doi: 10.3389/fmicb. 2021.614058. DOI: https://doi.org/10.3389/fmicb.2021.614058

M. S. Walters et al., “Carbapenem-Resistant Pseudomonas aeruginosa at US Emerging Infections Program Sites, 2015,” Emerging Infectious Diseases, vol. 25, no. 7, pp. 1281–1288, Jul. 2019, doi: 10.3201/eid2507.181200. DOI: https://doi.org/10.3201/eid2507.181200

A. Elfadadny et al., ‘’Antimicrobial resistance of Pseudomonas aeruginosa: navigating clinical impacts, current re-sistance trends, and innovations in breaking therapies,’’ Frontiers in Microbiology, vol. 15:1374466, Apr. 2024, doi: 10.3389/fmicb.2024.1374466.

M. R. Rao, P. Chandrashaker, R. P. Mahale, S. G. Shivappa, R. S. Gowda, and V. B. Chitharagi, “Detection of car-bapenemase production in Enterobacteriaceae and Pseudomonas species by carbapenemase Nordmann–Poirel test,” Journal of Laboratory Physicians, vol. 11, no. 02, pp. 107–110, Apr. 2019, doi: 10.4103/JLP.JLP_132_18. DOI: https://doi.org/10.4103/JLP.JLP_132_18

T. Ramatla et al., “Global prevalence and antibiotic resistance profiles of carbapenem-resistant Pseudomonas aeru-ginosa reported from 2014 to 2024: a systematic review and meta-analysis,” Frontiers in Microbiology, vol. 16, Jul. 2025, doi: 10.3389/fmicb.2025.1599070. DOI: https://doi.org/10.3389/fmicb.2025.1599070

M. T. Arowolo et al., “Prevalence of carbapenem resistance in Acinetobacter baumannii and Pseudomonas aerugino-sa in sub-Saharan Africa: A systematic review and meta-analysis,” PLOS ONE, vol. 18, no. 11, Article e0287762, Nov. 2023, doi: 10.1371/journal.pone.0287762. DOI: https://doi.org/10.1371/journal.pone.0287762

M.-G. Wang et al., “Retrospective Data Insight into the Global Distribution of Carbapenemase-Producing Pseudomo-nas aeruginosa,” Antibiotics, vol. 10, no. 5, p. 548, May 2021, doi: 10.3390/antibiotics10050548. DOI: https://doi.org/10.3390/antibiotics10050548

N. Verma, A. Prahraj, B. Mishra, B. Behera, and K. Gupta, “Detection of carbapenemase-producing Pseudomonas aeruginosa by phenotypic and genotypic methods in a tertiary care hospital of East India,” Journal of Laboratory Phy-sicians, vol. 11, no. 4, pp. 287–291, Oct. 2019, doi: 10.4103/JLP.JLP_136_19. DOI: https://doi.org/10.4103/JLP.JLP_136_19

G. Asokan, T. Ramadhan, E. Ahmed, and H. Sanad, “WHO Global Priority Pathogens List: A Bibliometric Analysis of Medline-PubMed for Knowledge Mobilization to Infection Prevention and Control Practices in Bahrain,” Oman Medical Journal, vol. 34, no. 3, pp. 184–193, May 2019, doi: 10.5001/omj.2019.37. DOI: https://doi.org/10.5001/omj.2019.37

B. A. Forbes, D. F. Sahm, and A. S. Weissfeld, Bailey & Scott’s Diagnostic Microbiology, 14th ed. St. Louis, MO, USA: Elsevier, 2017.

R. M. Satokari, E. E. Vaughan, A. D. L. Akkermans, M. Saarela, and W. M. de Vos, “Bifidobacterial Diversity in Human Feces Detected by Genus-Specific PCR and Denaturing Gradient Gel Electrophoresis,” Applied and Environ-mental Microbiology, vol. 67, no. 2, pp. 504–513, Feb. 2001, doi: 10.1128/AEM.67.2.504-513.2001. DOI: https://doi.org/10.1128/AEM.67.2.504-513.2001

S. Kumar, G. Stecher, M. Suleski, M. D. Sanderford, S. Sharma, and K. Tamura, “MEGA12: Molecular Evolutionary Genetics Analysis Version 12 for Adaptive and Green Computing,” Molecular Biology and Evolution, vol. 41, no. 12, msae263, Dec. 2024, doi: 10.1093/molbev/msae263. DOI: https://doi.org/10.1093/molbev/msae263

F. Cosentino, P. Viale, and M. Giannella, “MDR/XDR/PDR or DTR? Which definition best fits the resistance profile of Pseudomonas aeruginosa?” Current Opinion in Infectious Diseases, vol. 36, no. 6, pp. 564–571, Dec. 2023, doi: 10.1097/QCO.0000000000000966. DOI: https://doi.org/10.1097/QCO.0000000000000966

V. M. Pierce et al., “Modified Carbapenem Inactivation Method for Phenotypic Detection of Carbapenemase Produc-tion among Enterobacteriaceae,” Journal of Clinical Microbiology, vol. 55, no. 8, pp. 2321–2333, Aug. 2017, doi: 10.1128/JCM.00193-17. DOI: https://doi.org/10.1128/JCM.00193-17

M. Beig, M. Taheri, and M. R. Arabestani, “Comparison of Different Phenotypic Tests versus PCR in the Detection of Carbapenemase-Producing Pseudomonas aeruginosa Isolates in Hamadan, Iran,” International Journal of Microbiolo-gy, vol. 2021, pp. 1–8, Jul. 2021, doi: 10.1155/2021/5582615. DOI: https://doi.org/10.1155/2021/5582615

Y. M. Tsai, S. Wang, H. C. Chiu, C. Y. Kao, and L. L. Wen, “Combination of mCIM and eCIM for detection of car-bapenemase-producing Enterobacteriaceae,” BMC Microbiology, vol. 20, no. 1, p. 315, Dec. 2020, doi: 10.1186/s12866-020-02010-3. DOI: https://doi.org/10.1186/s12866-020-02010-3

K. Hu et al., “Antibiotic susceptibility and molecular analyses of clinical Enterobacter cloacae isolates in Eastern Hei-longjiang Province, China,” Annals of Palliative Medicine, vol. 9, no. 3, pp. 1211–1219, May 2020, doi: 10.21037/apm-20-1089. DOI: https://doi.org/10.21037/apm-20-1089

F. Meimani, R. Nazari, and M. N. Rostami, “Detection of metallo-beta-lactamase genes among Pseudomonas aerugino-sa,” Zahedan Journal of Research in Medical Sciences, vol. 20, no. 9, Article e59559, 2018, doi: 10.5812/zjrms.59559. DOI: https://doi.org/10.5812/zjrms.59559

B. C. Jeon et al., ‘’Investigation of a nosocomial outbreak of imipenem-resistant Acinetobacter baumannii producing the OXA-23 beta-lactamase in Korea,’’ Journal of Clinical Microbiology, vol. 43, no. 5, pp. 2241-2245, May 2005, doi: 10.1128/JCM.43.5.2241-2245.2005. DOI: https://doi.org/10.1128/JCM.43.5.2241-2245.2005

Y. Migiyama et al., “Airway Pseudomonas aeruginosa density in mechanically ventilated patients: clinical impact and relation to therapeutic efficacy of antibiotics,” Critical Care, vol. 25, no. 1, Article 59, Feb. 2021, doi: 10.1186/s13054-021-03488-7. DOI: https://doi.org/10.1186/s13054-021-03488-7

Ritu, S. S. Prasad, and A. Lal, “Clinical and microbiological profile of ventilator-associated pneumonia in ICU pa-tients,” International Journal of Pharmaceutical Quality Assurance, vol. 16, no. 11, pp. 416–421, 2025, doi: 10.25258/ijpqa.16.11.66.

H. Hu, H. Huang, Q. Peng, J. Lu, and X. Lei, “Prospective study of colonization and infection because of Pseudomo-nas aeruginosa in mechanically ventilated patients at a neonatal intensive care unit in China,” American Journal of In-fection Control, vol. 38, no. 9, pp. 746–750, Nov. 2010, doi: 10.1016/j.ajic.2010.02.012. DOI: https://doi.org/10.1016/j.ajic.2010.02.012

R. Sobala et al., “An observational study of Pseudomonas aeruginosa in adult long-term ventilation,” European Respira-tory Journal Open Research, vol. 8, no. 2, pp. 00687–02021, Apr. 2022, doi: 10.1183/23120541.00687-2021. DOI: https://doi.org/10.1183/23120541.00687-2021

P. Mergulhão et al., “Epidemiology and burden of ventilator-associated pneumonia among adult intensive care unit patients: A Portuguese, multicenter, retrospective study (eVAP-PT study),” Antibiotics, vol. 13, no. 4, p. 290, Mar. 2024, doi: 10.3390/antibiotics13040290. DOI: https://doi.org/10.3390/antibiotics13040290

F. Howroyd et al., “Ventilator-associated pneumonia: pathobiological heterogeneity and diagnostic challenges,” Na-ture Communications, vol. 15, Article 6447, 2024, doi: 10.1038/s41467-024-50805-z. DOI: https://doi.org/10.1038/s41467-024-50805-z

A. D. Harris et al., “Pseudomonas aeruginosa colonization in the intensive care unit: Prevalence, risk factors, and clinical outcomes,” Infection Control and Hospital Epidemiology, vol. 37, no. 5, pp. 544–548, May 2016, doi: 10.1017/ice.2015.346. DOI: https://doi.org/10.1017/ice.2015.346

S. Hoang et al., ‘’Risk factors for colonization and infection by Pseudomonas aeruginosa in patients hospitalized in intensive care units in France,’’ PLOS ONE, Vol. 13, no. 3, Article e0193300, Mar. 2018, https://doi.org/10.1371/journal.pone.0193300. DOI: https://doi.org/10.1371/journal.pone.0193300

A. Boyer et al., “Pseudomonas aeruginosa acquisition on an intensive care unit: relationship between antibiotic selec-tive pressure and patients’ environment,” Critical Care, vol. 15, no. 1, p. R55, Feb. 2011, doi: 10.1186/cc10026. DOI: https://doi.org/10.1186/cc10026

P. R. Murray, K. S. Rosenthal, and M. A. Pfaller, Medical Microbiology, 9th ed. Elsevier, 2021.

M. Bassetti, A. Vena, A. Croxatto, E. Righi, and B. Guery, “How to manage Pseudomonas aeruginosa infections,” Drugs in Context, vol. 7, pp. 1–18, May 2018, doi: 10.7573/dic.212527. DOI: https://doi.org/10.7573/dic.212527

N. G. Naga, D. E. El-Badan, M. E. M. Mabrouk, H. S. Rateb, K. M. Ghanem, and M. I. Shaaban, “Innovative applica-tion of ceftriaxone as a quorum-sensing inhibitor in Pseudomonas aeruginosa,” Scientific Reports, vol. 15, Article 5022, 2025, doi: 10.1038/s41598-025-87609-0. DOI: https://doi.org/10.1038/s41598-025-87609-0

A. Karruli et al., “Evidence-based treatment of Pseudomonas aeruginosa infections: a critical reappraisal,” Antibiot-ics, vol. 12, no. 2, Article 399, 2023, doi: 10.3390/antibiotics12020399. DOI: https://doi.org/10.3390/antibiotics12020399

R. Itani et al., “Difficult-to-treat resistant Pseudomonas aeruginosa infections in Lebanese hospitals: Impact on mor-tality and the role of initial antibiotic therapy,” PLOS ONE, vol. 20, no. 5, Article e0321935, May 2025, doi: 10.1371/journal.pone.0321935. DOI: https://doi.org/10.1371/journal.pone.0321935

A. D. Khosravi, S. Taee, A. A. Dezfuli, H. Meghdadi, and F. Shafie, “Investigation of the prevalence of genes confer-ring resistance to carbapenems in Pseudomonas aeruginosa isolates from burn patients,” Infection and Drug Re-sistance, vol. 12, pp. 1153–1159, May 2019, doi: 10.2147/IDR.S197752. DOI: https://doi.org/10.2147/IDR.S197752

Z. K. Çekin et al., “Carbapenemase -producing Pseudomonas aeruginosa isolates from Turkey: first report of P. ae-ruginosa high-risk clones with VIM-5– and IMP-7–type carbapenemases in a tertiary hospital,” Diagnostic Microbiolo-gy and Infectious Disease, vol. 99, no. 1, p. 115174, Jan. 2021, doi: 10.1016/j.diagmicrobio.2020.115174.

G. Malkoçoğlu, E. Aktaş, B. Bayraktar, B. Otlu, and M. E. Bulut, “VIM-1, VIM-2, and GES-5 Carbapenemases Among Pseudomonas aeruginosa Isolates at a Tertiary Hospital in Istanbul, Turkey,” Microbial Drug Resistance, vol. 23, no. 3, pp. 328–334, Apr. 2017, doi: 10.1089/mdr.2016.0012. DOI: https://doi.org/10.1089/mdr.2016.0012

M. Saravanan, M. A. Belete, and J. Arockiaraj, “Carbapenem-resistant Pseudomonas aeruginosa in intensive care units increase mortality as an emerging global threat,” International Journal of Surgery, vol. 109, no. 4, pp. 1034–1036, Apr. 2023, doi: 10.1097/JS9.0000000000000184. DOI: https://doi.org/10.1097/JS9.0000000000000184

J. P. Horcajada et al., “Current and future options for the treatment of serious infections due to carbapenem-resistant Pseudomonas aeruginosa,” Clinical Microbiology Reviews, vol. 38, no. 4, Dec. 2025, doi: 10.1128/cmr.00233-24. DOI: https://doi.org/10.1128/cmr.00233-24

P. Saengsuwan, N. Kositpantawong, S. Kawila, W. Patugkaro, and C. Romyasamit, “Prevalence of carbapenemase genes among multidrug-resistant Pseudomonas aeruginosa isolates from tertiary care centers in Southern Thailand,” Saudi Medical Journal, vol. 43, no. 9, pp. 991–999, Sep. 2022, doi: 10.15537/smj.2022.43.9.20220219. DOI: https://doi.org/10.15537/smj.2022.43.9.20220219

G. De Pascale et al., “Incidence of hospital-acquired infections due to carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa in critically ill patients in Italy: a multicentre prospective cohort study,” Critical Care, vol. 29, no. 1, p. 32, Jan. 2025, doi: 10.1186/s13054-025-05266-1. DOI: https://doi.org/10.1186/s13054-025-05266-1

W. Huang, X. Wei, G. Xu, X. Zhang, and X. Wang, “Carbapenem-resistant Pseudomonas aeruginosa infections in critically ill children: Prevalence, risk factors, and impact on outcome in a large tertiary pediatric hospital of China,” Frontiers in Public Health, vol. 11, Article 1088262, Feb. 2023, doi: 10.3389/fpubh.2023.1088262. DOI: https://doi.org/10.3389/fpubh.2023.1088262

M. Al-Orphaly et al., “Epidemiology of Multidrug-Resistant Pseudomonas aeruginosa in the Middle East and North Africa Region,” mSphere, vol. 6, no. 3, Jun. 2021, doi: 10.1128/mSphere.00202-21. DOI: https://doi.org/10.1128/mSphere.00202-21

S. Baban, “Molecular detection of carbapenemase-producing Pseudomonas aeruginosa isolated from intensive care units of surgical specialty hospital in Erbil city,” Medical Journal of Babylon, vol. 17, no. 2, p. 185, 2020, doi: 10.4103/MJBL.MJBL_24_20. DOI: https://doi.org/10.4103/MJBL.MJBL_24_20

M. E. Hassan et al., “Causative bacteria of ventilator-associated pneumonia in intensive care unit in Bahrain: Preva-lence and antibiotics susceptibility pattern,” World Journal of Critical Care Medicine, vol. 12, no. 3, pp. 165–175, Jun. 2023, doi: 10.5492/wjccm.v12.i3.165. DOI: https://doi.org/10.5492/wjccm.v12.i3.165

T. Akter, S. Islam, A. M. Haider, K. Fatema, F. Stapleton, and M. Willcox, “Antibiotic resistance mechanisms and global resistance patterns of Pseudomonas aeruginosa in microbial keratitis,” European Journal of Clinical Microbiology & Infectious Diseases, Mar. 2026, doi: 10.1007/s10096-026-05484-7. DOI: https://doi.org/10.1007/s10096-026-05484-7

M. Wang, Y. Zhang , F. Pei , Y. Liu, and Y. Zheng, “Loss of OprD function is sufficient for carbapenem-resistance-only but insufficient for multidrug resistance in Pseudomonas aeruginosa,” BMC Microbiology, vol. 25, no. 1, Article 218, Apr. 2025, doi: 10.1186/s12866-025-03935-3. DOI: https://doi.org/10.1186/s12866-025-03935-3

L. Yin et al., “Non-carbapenem-producing carbapenem-resistant Pseudomonas aeruginosa in children: Risk factors, molecular epidemiology, and resistance mechanism,” Journal of Infection and Public Health, vol. 18, no. 2, Article 102634, Feb. 2025, doi: 10.1016/j.jiph.2024.102634. DOI: https://doi.org/10.1016/j.jiph.2024.102634

Z. Kalaycı Çekin, E. S. Tanrıverdi, and B. Otlu, “Investigation of Carbapenemase-Producing Pseudomonas aeruginosa at Secondary Care Hospital in Bolu, Turkey,” Microbial Drug Resistance, vol. 30, no. 11, pp. 450–457, Nov. 2024, doi: 10.1089/mdr.2024.0067. DOI: https://doi.org/10.1089/mdr.2024.0067

H. O. Alshammari, A. M. Albarrag, I. M. Moussa, J. A. Al-Tawfiq, S. A. Aldakeel, and A. M. Somily, “Molecular analysis of carbapenemase-producing Pseudomonas aeruginosa strains in a tertiary care hospital in Riyadh,” Journal of Infection and Public Health, vol. 19, no. 4, p. 103159, Apr. 2026, doi: 10.1016/j.jiph.2026.103159. DOI: https://doi.org/10.1016/j.jiph.2026.103159

A. Elfadadny et al., “Antimicrobial resistance of Pseudomonas aeruginosa: navigating clinical impacts, current re-sistance trends, and innovations in breaking therapies,” Frontiers in Microbiology, vol. 15, Article 1374466, Apr. 2024, doi: 10.3389/fmicb.2024.1374466. DOI: https://doi.org/10.3389/fmicb.2024.1374466

H. A. Aal Owaif, M. K. Aldulaimy, and S. A. Abdulateef, ‘’The Antibiotic Resistance Genes blaSHV, blaOXA-48, blaTEM and blaIMP in Pseudomonas aeruginosa Isolated from Respiratory Tract Infections in Baghdad, Iraq,’’ Inter-national Journal of Biomedicine, vol. 13, no. 4, pp. 341-344, Dec. 2023, doi:10.21103/Article13(4)_OA18. DOI: https://doi.org/10.21103/Article13(4)_OA18

Z. K. Çekin et al., “Carbapenemase -producing Pseudomonas aeruginosa isolates from Turkey: first report of P. ae-ruginosa high-risk clones with VIM-5– and IMP-7–type carbapenemases in a tertiary hospital,” Diagnostic Microbiolo-gy and Infectious Disease, vol. 99, no. 1, p. 115174, Jan. 2021, doi: 10.1016/j.diagmicrobio.2020.115174. DOI: https://doi.org/10.1016/j.diagmicrobio.2020.115174

S. Mohamed et al., “Co-occurrence of carbapenemase genes blaNDM, blaVIM, blaKPC, and blaOXA-48 in Pseudo-monas aeruginosa clinical isolates,” International Journal of Biomedicine, vol. 13, no. 3, pp. 123–126, Sep. 2023, doi: 10.21103/Article13(3)_OA12. DOI: https://doi.org/10.21103/Article13(3)_OA12

K. Zhu, S. Li, Z. Guo, Ch. Xiao, and Q. Wei, “Antimicrobial resistance mechanisms in carbapenem-resistant Pseudo-monas aeruginosa Clinical Strains Isolated in Shanghai, China,” Polish Journal of Microbiology, vol. 74, no. 3, pp. 275–288, Sep. 2025, doi: 10.33073/pjm-2025-022. DOI: https://doi.org/10.33073/pjm-2025-022